IE
TARS icon

Israel Englander’s Tarsus Pharmaceuticals TARS Stock Holding History

Israel Englander’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.89M Hold
30,000
– – ﹤0.01% 3866
2026
Q1 		$2.1M Buy
30,000
+10,000
+50% +$699K ﹤0.01% 3831
2025
Q4 		$1.64M Buy
+20,000
New +$1.49M ﹤0.01% 4105

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Israel Englander's TARS Position: Q2 2026 in Review

Israel Englander increased its Tarsus Pharmaceuticals (TARS) stake by 153% in Q2 2026, buying an estimated $55.1M and bringing the position to 1,427,124 shares worth $89.8M. The position accounts for 0.03% of the portfolio, ranked #556.

Israel Englander first reported a position in TARS in Q4 2020 and has held it in 16 quarters since. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Israel Englander held 1,427,124 shares of Tarsus Pharmaceuticals worth $89.8M as of Q2 2026.
  • Israel Englander bought 862,545 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $55.1M.
  • Tarsus Pharmaceuticals made up 0.03% of Israel Englander's portfolio in Q2 2026, its #556 holding.
  • Israel Englander first reported a position in Tarsus Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.